Switch theme
Sign up to access all valuation multiples
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
2002
1.5K+
LTM Revenue $314M
LTM EBITDA $57.2M
$458M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Takara Bio has a last 12-month revenue (LTM) of $314M and a last 12-month EBITDA of $57.2M.
In the most recent fiscal year, Takara Bio achieved revenue of $299M and an EBITDA of $54.2M.
Takara Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Takara Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $314M | XXX | $299M | XXX | XXX | XXX |
| Gross Profit | $183M | XXX | $185M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | $57.2M | XXX | $54.2M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $19.3M | XXX | $20.6M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $10.8M | XXX | $10.2M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Takara Bio's stock price is JPY 791 (or $5).
Takara Bio has current market cap of JPY 95.2B (or $654M), and EV of JPY 66.8B (or $458M).
See Takara Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $458M | $654M | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Takara Bio has market cap of $654M and EV of $458M.
Takara Bio's trades at 1.3x EV/Revenue multiple, and 5.4x EV/EBITDA.
Equity research analysts estimate Takara Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Takara Bio has a P/E ratio of 60.3x.
See valuation multiples for Takara Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $654M | XXX | $654M | XXX | XXX | XXX |
| EV (current) | $458M | XXX | $458M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 8.0x | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBIT | 23.7x | XXX | 9.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 60.3x | XXX | 18.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -108.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTakara Bio's last 12 month revenue growth is 8%
Takara Bio's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Takara Bio's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Takara Bio's rule of X is 38% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Takara Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | -2% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | -8% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Corbion | XXX | XXX | XXX | XXX | XXX | XXX |
| Gujarat State Fertilizers & Chemicals | XXX | XXX | XXX | XXX | XXX | XXX |
| Industries Qatar | XXX | XXX | XXX | XXX | XXX | XXX |
| K+S | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Takara Bio acquired XXX companies to date.
Last acquisition by Takara Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Takara Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Takara Bio founded? | Takara Bio was founded in 2002. |
| Where is Takara Bio headquartered? | Takara Bio is headquartered in Japan. |
| How many employees does Takara Bio have? | As of today, Takara Bio has 1.5K+ employees. |
| Who is the CEO of Takara Bio? | Takara Bio's CEO is Mr. Koichi Nakao. |
| Is Takara Bio publicy listed? | Yes, Takara Bio is a public company listed on TKS. |
| What is the stock symbol of Takara Bio? | Takara Bio trades under 4974 ticker. |
| When did Takara Bio go public? | Takara Bio went public in 2004. |
| Who are competitors of Takara Bio? | Similar companies to Takara Bio include e.g. Fertiglobe, Corbion, Gujarat State Fertilizers & Chemicals, Industries Qatar. |
| What is the current market cap of Takara Bio? | Takara Bio's current market cap is $654M |
| What is the current revenue of Takara Bio? | Takara Bio's last 12 months revenue is $314M. |
| What is the current revenue growth of Takara Bio? | Takara Bio revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Takara Bio? | Current revenue multiple of Takara Bio is 1.5x. |
| Is Takara Bio profitable? | Yes, Takara Bio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Takara Bio? | Takara Bio's last 12 months EBITDA is $57.2M. |
| What is Takara Bio's EBITDA margin? | Takara Bio's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Takara Bio? | Current EBITDA multiple of Takara Bio is 8.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
